GPER has been proposed to act as tumor suppressor in ovarian cancer [105] and to have, together with Wnt pathway modulator Dickkopf 2 (Dkk2) expression, a positive prognostic impact in ovarian cancer patients [106,107]. The gene discussed is DKK2; the disease is ovarian carcinoma.